Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats
- 1 February 1995
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 273 (3) , 215-221
- https://doi.org/10.1016/0014-2999(94)00682-w
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Improved Therapy of Parkinsonʼs Disease with Tolcapone, a Central and Peripheral COMT Inhibitor with an S-Adenosyl-L-Methionine-Sparing EffectClinical Neuropharmacology, 1994
- Effects of Catechol-O-Methyltransferase Inhibitors and L-3,4-Dihydroxyphenylalanine With or Without Carbidopa on Extracellular Dopamine in Rat StriatumJournal of Neurochemistry, 1993
- Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis studyBrain Research, 1992
- Extracellular Concentrations of Dopamine and Metabolites in the Rat Caudate After Oral Administration of a Novel Catechol‐O‐Methyltransferase Inhibitor Ro 40–7592Journal of Neurochemistry, 1992
- Catechol‐ O ‐methyltransferase inhibition increases striatal L‐dopa and dopamineNeurology, 1992
- Interstitial 3-Methoxytyramine Reflects Striatal Dopamine Release: An In Vivo Microdialysis StudyJournal of Neurochemistry, 1991
- New Therapeutic Strategies in Parkinson’s Disease: Inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592Published by Springer Nature ,1991
- Clinical Pharmacokinetics of Anti-Parkinsonian DrugsClinical Pharmacokinetics, 1987
- The pharmacology of Parkinson's disease: Basic aspects and recent advancesCellular and Molecular Life Sciences, 1984
- Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolitesJournal of Neuroscience, 1984